secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001193125-23-138948
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon Q1 net loss $12.8M vs $7.2M YoY; cash $159.5M; FDA Fast Track for ACR-368
--------------------------------------------------------------------------------

- Net loss $12.8M for Q1 2023, widened from $7.2M in Q1 2022; R&D expense $9.8M (up from $6.1M).
- Cash, equivalents and marketable securities $159.5M as of March 31, 2023; runway into Q4 2024.
- FDA granted Fast Track designation for ACR-368 monotherapy in OncoSignature-positive platinum-resistant ovarian and endometrial cancer.
- Phase 2 registrational trial of ACR-368 continues enrolling; initial clinical readouts expected H2 2023.
- Advancing WEE1 and PKMYT1 inhibitor programs toward IND-enabling studies in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000119312523138948/0001193125-23-138948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000119312523138948/d421791d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-138948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer